Although a selection between aptamers and a target could be carried out and optimized under any condition, aptamers can be applied not only to diagnosis, but also to therapy[8, 9] such as Pegaptanib, which is an FDA approved anti-vascular endothelial growth factor (anti-VEGF) RNA aptamer for the treatment of an age-related macular degeneration [10]. Here, VEGFA is linked to age-related macular degeneration.